Homepage>Company>Media>Pharma News>2024>GSK has unveiled positive data from its Phase III AReSVi-006 clinical trial of Arexvy, its RSV vaccine, which aims to prevent lower respiratory tract disease (LRTD) over three RSV seasons.
GSK has unveiled positive data from its Phase III AReSVi-006 clinical trial of Arexvy, its RSV vaccine, which aims to prevent lower respiratory tract disease (LRTD) over three RSV seasons.